{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Grade+III+Glioma",
    "query": {
      "condition": "Recurrent Grade III Glioma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 130,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Grade+III+Glioma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T19:14:19.926Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00572182",
      "title": "MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "MK-0752",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 33,
      "start_date": "2008-07",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 12,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00572182"
    },
    {
      "nct_id": "NCT00788125",
      "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Liver Cancer",
        "Lymphoma",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Testicular Germ Cell Tumor",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "western blotting",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 7,
      "start_date": "2008-09-03",
      "completion_date": "2022-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00788125"
    },
    {
      "nct_id": "NCT04573140",
      "title": "A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Glioblastoma",
        "High Grade Glioma",
        "WHO Grade III or IV Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2021-12-13",
      "completion_date": "2029-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573140"
    },
    {
      "nct_id": "NCT00030108",
      "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Leukemia",
        "Liver Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2001-11",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030108"
    },
    {
      "nct_id": "NCT03914742",
      "title": "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "IDH1 Mutation",
        "IDH2 Mutation",
        "Recurrent Glioblastoma",
        "Recurrent WHO Grade II Glioma",
        "Recurrent WHO Grade III Glioma"
      ],
      "interventions": [
        {
          "name": "PARP Inhibitor BGB-290",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2020-02-16",
      "completion_date": "2023-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03914742"
    },
    {
      "nct_id": "NCT03450850",
      "title": "Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Astrocytoma, Grade III"
      ],
      "interventions": [
        {
          "name": "NOVOTTF-200A",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Daniela A. Bota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-05-21",
      "completion_date": "2025-08-07",
      "has_results": true,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03450850"
    },
    {
      "nct_id": "NCT00946335",
      "title": "ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Ependymoblastoma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebellar Astrocytoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebellar Astrocytoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Medulloepithelioma",
        "Childhood Mixed Glioma",
        "Childhood Oligodendroglioma",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Pineoblastoma",
        "Recurrent Childhood Spinal Cord Neoplasm",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma"
      ],
      "interventions": [
        {
          "name": "veliparib",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 31,
      "start_date": "2009-07",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-09",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00946335"
    },
    {
      "nct_id": "NCT02575794",
      "title": "Terameprocol in Treating Patients With Recurrent High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Grade Glioma (III or IV)"
      ],
      "interventions": [
        {
          "name": "Terameprocol",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-05-03",
      "completion_date": "2023-10-04",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575794"
    },
    {
      "nct_id": "NCT05084430",
      "title": "Study of Pembrolizumab and M032 (NSC 733972)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "M032",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2022-02-25",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084430"
    },
    {
      "nct_id": "NCT00014573",
      "title": "Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous tumor cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-08",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2013-04-08",
      "last_synced_at": "2026-06-25T19:14:19.926Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014573"
    }
  ]
}